{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:00:58Z","timestamp":1795122058706,"version":"4.10.3"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>The aim of this open-label, multicenter, randomized controlled study was to investigate whether the life cycle pharma (LCP)-tacrolimus compared with the extended-release (ER)-tacrolimus formulation results in a difference in the prevalence of posttransplant diabetes, hypertension and chronic kidney disease (CKD) at 12 mo after liver transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>Patients were 1:1 randomized to either of the 2 tacrolimus formulations. The primary endpoint was defined as a composite endpoint of any of 3 events: sustained (&gt;3 mo postrandomization) posttransplant diabetes, new-onset hypertension, and\/or CKD, defined as estimated glomerular filtration rate &lt;60\u2009mL\/min\/1.73 m<jats:sup>2<\/jats:sup> for &gt;3 m during the follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>In total, 105 patients were included. In the intention-to-treat analysis, a statistically significant lower proportion of liver transplant recipients in the LCP-tacrolimus group reached the composite primary endpoint at 12 mo compared with the ER-tacrolimus group (50.9% [27\/53], 95% confidence interval [CI], 37.9%-63.9% versus 71.2% [37\/52], 95% CI, 57.7%-81.7%; risk difference: 0.202; 95% CI, 0.002-0.382; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.046). No significant difference was found in the per protocol analysis. In the intention-to-treat and per protocol population, fewer liver transplant recipients in the LCP-tacrolimus group developed CKD and new-onset hypertension compared with the ER-tacrolimus group. No differences in rejection rate, graft and patient survival were found.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>A statistically significant and clinically relevant reduction in the prevalence of the composite primary endpoint was found in the LCP-tacrolimus group compared with the ER-tacrolimus group in the first year after liver transplantation with comparable efficacy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001612","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T02:00:22Z","timestamp":1710295222000},"page":"e1612","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Modifying Tacrolimus-related Toxicity After Liver Transplantation Comparing Life Cycle Pharma Tacrolimus Versus Extended-released Tacrolimus: A Multicenter, Randomized Controlled Trial"],"prefix":"10.1097","volume":"10","author":[{"given":"Midas B.","family":"Mulder","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."},{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"van Hoek","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojtek G.","family":"Polak","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."},{"name":"Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian P.J.","family":"Alwayn","sequence":"additional","affiliation":[{"name":"Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda C.M.","family":"de Winter","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."},{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarwa","family":"Darwish Murad","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."},{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Verhey-Hart","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."},{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Elshove","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."},{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole S.","family":"Erler","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."},{"name":"Department of Epidemiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Hesselink","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."},{"name":"Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"den Hoed","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."},{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herold J.","family":"Metselaar","sequence":"additional","affiliation":[{"name":"Erasmus MC Transplant Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands."},{"name":"Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"R1-20240805","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00000658-199009000-00008","article-title":"Liver, kidney, and thoracic organ transplantation under FK 506.","volume":"212","author":"Todo","year":"1990","journal-title":"Ann Surg"},{"key":"R2-20240805","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/SLA.0000000000002650","article-title":"No gains in long-term survival after liver transplantation over the past three decades.","volume":"269","author":"Rana","year":"2019","journal-title":"Ann Surg"},{"key":"R3-20240805","first-page":"839","article-title":"Randomized trial of ciclosporin with 2-h Monitoring vs. tacrolimus with trough monitoring in liver transplantation: DELTA study.","volume":"11","author":"Ruijter","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/biomedicines10020272","article-title":"Reducing the pill burden: immunosuppressant adherence and safety after conversion from a twice-daily (IR-Tac) to a novel once-daily (LCP-Tac) tacrolimus formulation in 161 liver transplant patients.","volume":"10","author":"Maurer","year":"2022","journal-title":"Biomedicines"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"7915781","DOI":"10.1155\/2023\/7915781","article-title":"Improved medication adherence with the use of extended-release tacrolimus in liver transplant recipients: a pilot randomized controlled trial.","volume":"2023","author":"Verma","year":"2023","journal-title":"J Transplant"},{"issue":"4S Suppl 2","key":"R6-20240805","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/TP.0000000000001651","article-title":"Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group.","volume":"101","author":"Neuberger","year":"2017","journal-title":"Transplantation"},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1097\/TP.0000000000002760","article-title":"Area under trough concentrations of tacrolimus as a predictor of progressive renal impairment after liver transplantation.","volume":"103","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2019","journal-title":"Transplantation"},{"key":"R8-20240805","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation.","volume":"22","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2022","journal-title":"Am J Transplant"},{"key":"R9-20240805","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1600-6143.2010.03126.x","article-title":"Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study.","volume":"10","author":"Watt","year":"2010","journal-title":"Am J Transplant"},{"key":"R10-20240805","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/lt.21126","article-title":"Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events.","volume":"13","author":"Laryea","year":"2007","journal-title":"Liver Transpl"},{"key":"R11-20240805","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2014.03.034","article-title":"Chronic kidney disease and associated mortality after liver transplantation\u2014a time-dependent analysis using measured glomerular filtration rate.","volume":"61","author":"Allen","year":"2014","journal-title":"J Hepatol"},{"key":"R12-20240805","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/LVT.0000000000000003","article-title":"Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: a multicenter, randomized, controlled trial.","volume":"29","author":"Mulder","year":"2023","journal-title":"Liver Transpl"},{"key":"R13-20240805","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/lt.24137","article-title":"Cardiovascular disease after liver transplantation: when, what, and who is at risk.","volume":"21","author":"Fussner","year":"2015","journal-title":"Liver Transpl"},{"key":"R14-20240805","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ajt.13935","article-title":"A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study.","volume":"17","author":"Tremblay","year":"2017","journal-title":"Am J Transplant"},{"key":"R15-20240805","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1111\/ajt.12955","article-title":"Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial.","volume":"14","author":"Budde","year":"2014","journal-title":"Am J Transplant"},{"key":"R16-20240805","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40265-015-0349-2","article-title":"Tacrolimus prolonged release (Envarsus(R)): a review of its use in kidney and liver transplant recipients.","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"key":"R17-20240805","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40262-015-0282-2","article-title":"Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients.","volume":"54","author":"Staatz","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/TP.0000000000002052","article-title":"High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes.","volume":"102","author":"Rayar","year":"2018","journal-title":"Transplantation"},{"key":"R19-20240805","first-page":"3175","article-title":"Neurologic complications of FK 506.","volume":"23","author":"Eidelman","year":"1991","journal-title":"Transplant Proc"},{"key":"R20-20240805","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1399-0012.2005.00359.x","article-title":"Guidelines for the treatment and management of new-onset diabetes after transplantation.","volume":"19","author":"Wilkinson","year":"2005","journal-title":"Clin Transplant"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabet Med"},{"key":"R22-20240805","first-page":"5","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"3","author":"Eknoyan","year":"2013","journal-title":"Kidney Int"},{"key":"R23-20240805","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions.","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R24-20240805","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/TP.0000000000002680","article-title":"High intrapatient variability in tacrolimus exposure is not associated with immune-mediated graft injury after liver transplantation.","volume":"103","author":"van der Veer","year":"2019","journal-title":"Transplantation"},{"key":"R27-20240805","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.ackd.2010.10.006","article-title":"Hypertension following kidney transplantation.","volume":"18","author":"Rubin","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"R28-20240805","doi-asserted-by":"crossref","first-page":"602764","DOI":"10.3389\/fphar.2021.602764","article-title":"Tacrolimus intrapatient variability after switching from immediate or prolonged-release to extended-release formulation, after an organ transplantation.","volume":"12","author":"Del Bello","year":"2021","journal-title":"Front Pharmacol"},{"key":"R29-20240805","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/tri.12798","article-title":"A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation.","volume":"29","author":"Shuker","year":"2016","journal-title":"Transpl Int"},{"key":"R30-20240805","doi-asserted-by":"crossref","first-page":"e13767","DOI":"10.1111\/ctr.13767","article-title":"Effectiveness and safety of the conversion to MeltDose(\u00ae) extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: a retrospective study.","volume":"34","author":"S\u00e1nchez Fructuoso","year":"2020","journal-title":"Clin Transplant"},{"key":"R31-20240805","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1016\/j.transproceed.2019.03.084","article-title":"MeltDose technology vs once-daily prolonged release tacrolimus in de novo liver transplant recipients.","volume":"51","author":"Baccarani","year":"2019","journal-title":"Transplant Proc"},{"key":"R32-20240805","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/lt.23844","article-title":"Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.","volume":"20","author":"Alloway","year":"2014","journal-title":"Liver Transpl"},{"key":"R33-20240805","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/TP.0000000000004095","article-title":"Five-year outcome of an early everolimus-based quadruple immunosuppression in lung transplant recipients: follow-up of the 4EVERLUNG study.","volume":"106","author":"Kneidinger","year":"2022","journal-title":"Transplantation"},{"key":"R34-20240805","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.healun.2014.06.001","article-title":"Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.","volume":"34","author":"Glanville","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"R35-20240805","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13063-023-07344-7","article-title":"EnGraft: a multicentre, open-label, randomised, two-arm, superiority study protocol to assess bioavailability and practicability of Envarsus\u00ae versus Advagraf\u2122 in liver transplant recipients.","volume":"24","author":"W\u00f6hl","year":"2023","journal-title":"Trials"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T04:02:09Z","timestamp":1722830529000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001612","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}